Phase 2 Post-Transplant Lymphoproliferative Disorder Clinical Trials
4 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–4 of 4 trials
Recruiting
Phase 2
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder
Timothy Voorhees28 enrolled4 locationsNCT05786040
Recruiting
Phase 1Phase 2
EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation
Post-Transplant Lymphoproliferative DisorderEBV-DNA Viremia
Daihong Liu18 enrolled1 locationNCT07438067
Recruiting
Phase 1Phase 2
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Post-Transplant Lymphoproliferative DisorderEpstein-Barr Virus Infection
Daihong Liu18 enrolled1 locationNCT07368634
Recruiting
Phase 2
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Recurrent Follicular LymphomaRefractory Follicular LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+8 more
University of Washington40 enrolled1 locationNCT05453396